Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate

Leukemia Research

Volumn 32, Issue 2, 2008, Pages 255-261

  Alimena, Giuliana ^a   Breccia, Massimo ^a   Luciano, Luigia ^b   Quarantelli, Fabrizio ^b   Diverio, Daniela ^a   Izzo, Barbara ^b   De Angelis, Biagio ^b   Mancini, Marco ^a   Latagliata, Roberto ^a   Carmosino, Ida ^a   Nanni, Mauro ^a   Picardi, Marco ^b   Rotoli, Bruno ^b   Mandelli, Franco ^a   Pane, Fabrizio ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Chronic myeloid leukemia; Imatinib; Interferon alpha; Minimal residual disease

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; MINIMAL RESIDUAL DISEASE; PHILADELPHIA CHROMOSOME POSITIVE CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; NEOPLASM, RESIDUAL; PIPERAZINES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 38949094536     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.06.008     Document Type: Article

References (29)

1. Daley G.Q., Van Etten R.A., and Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247 (1990) 824-830
2. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330 (1994) 820-825
3. Hehlmann R., Berger U., Pfirrmann M., et al. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 17 (2003) 1529-1537
4. Hochhaus A., Reiter A., Saussele S., et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood 95 (2000) 62-66
5. Bonifazi F., de Vivo A., Rosti G., et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98 (2001) 3074-3081
6. Mahon F.X., Delbrel X., Cony-Makhoul P., et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 20 (2002) 214-220
7. Kantarjian H.M., O'Brien S., Cortes J., et al. Complete cytogenetic and molecular responses to IFN-alpha based therapy for chronic myeloid leukemia are associated with excellent long-term prognosis. Cancer 97 (2003) 1033-1041
8. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1031-1037
9. Kantarjian H.M., Cortes J.E., O'Brien S., et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive, chronic-phase chronic myeloid leukemia after failure of interferon-{alpha}. Blood 104 (2004) 1979-1988
10. O'Brien S.G., Guilhot F., Larson R.A., et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
11. Branford S., Rudzki Z., Harper A., et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 17 (2003) 2401-2409
12. Druker B.J., Guilhot F.G., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (2006) 2408-2417
13. Hughes T.P., Kaeda J., Branford S., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349 (2003) 1423-1432
14. Muller M.C., Gattermann N., Lahaye T., et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia 17 (2003) 2392-2400
15. Paschka P., Muller M.C., Merx K., et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pre-treated with interferon alpha, low levels of residual disease are associated with continuous remission. Leukemia 17 (2003) 1687-1694
16. Hochhaus A., and La Rosee P. Imatinib therapy in chronic myelogenous leukaemia: strategies to avoid and overcome resistance. Leukemia 18 (2004) 1321-1331
17. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leucemia:recommendations from an export panel on behalf of the European LeukemiaNet. Blood 108 (2006) 1809-1820
18. Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346 (2002) 645-652
19. van Dongen J.J., Macintyre E.A., Gabert J.A., et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13 (1999) 1901-1928
20. Gabert J., Beillard E., van der Velden V.H., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukaemia-a Europe Against Cancer program. Leukemia 17 (2003) 2318-2357
21. Chronic myeloid leukaemia Trialists' Collaborative Group. Interferon alpha versus chemotherapy for chronic myeloid leukaemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst. 89 (1997) 1616-1620
22. Guilhot F., Chastang C., Michallet M., et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 337 (1997) 223-229
23. Kantarjian H., Talpaz M., O'Brien S., et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103 (2004) 2873-2878
24. Mauro M.J., and Deininger M.W. Chronic myeloid leukemia in 2006: a perspective. Haematologica 91 (2006) 152
25. Branford S., Rudzki Z., Parkinson I., et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 104 (2004) 2926-2932
26. Baccarani M., Martinelli G., Rosti G., et al. GIMEMA Working Party on Chronic Myeloid Leukemia. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 104 (2004) 4245-4251
27. Bhatia R., Holtz M., Niu N., et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101 (2003) 4701-4707
28. Rousselot P., Huguet F., Rea D., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109 (2007) 58-60
29. Hehlmann R., Berger U., and Hochhaus A. Chronic myeloid leukemia: a model for oncology. Ann Hematol 84 (2005) 487-497